oral glp 1 drugs in development Lilly is now pharma's top revenue company. It just got FDA approval for an GLP-1, but Wall Street isn't celebrating Oral GLP-1 Drug Development Trends:
Description
27 In addition, GLP-1R agonists improve glycemic control, especially in individuals with insulin resistance or type 2 diabetes, further reinforcing their clinical utility
V., Wu, B., Liu, Y
Curr Diabetes Rep (2018) 18(7):45
SubQ, subcutaneously
VSMC dysfunction can be defined as the occurrence of excessive proliferation, autophagy, fibrosis, senescence, and phenotypic transformation
Some of the early concern came from people I respected, including Peter Attia, who flagged lean-mass loss on scans in his own practice
